Type 2 inflammatory cytokines and eotaxins (Th2/Eotaxin)

Th2 cytokines and eotaxin expression refers to the collective production and signaling of key mediators in the Type 2 inflammatory pathway, primarily Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interleukin-13 (IL-13), and the eotaxin family of chemokines (CCL11, CCL24, CCL26) (Source: [1]). These molecules are central to the pathophysiology of allergic diseases such as asthma and atopic dermatitis, where they drive eosinophil recruitment, IgE production, and airway hyperresponsiveness (Source: PubMed: 32821219). While not a single molecular target, this group of mediators is frequently used as a pharmacodynamic readout to evaluate the efficacy of therapies targeting allergic inflammation. Drugs such as Dupilumab (targeting IL-4Ra), Mepolizumab (targeting IL-5), and Benralizumab (targeting IL-5Ra) work by specifically inhibiting individual components of this pathway, thereby reducing the overall inflammatory burden (Source: GSK, AstraZeneca, Sanofi). Monitoring these expression levels and associated biomarkers like blood eosinophils and FeNO is crucial for patient selection and assessing treatment response in clinical settings.

Other names

Th2 cytokine profileType 2 cytokinesEotaxin familyAllergic inflammatory mediatorsTh2-driven inflammatory markers

Neutralization of cytokines, receptor antagonism, inhibition of upstream signaling, and suppression of gene transcription.